+ All Categories
Home > Documents > Newer Antidiabetic Agents.pptx

Newer Antidiabetic Agents.pptx

Date post: 13-Apr-2015
Category:
Upload: priyanka-malla
View: 14 times
Download: 2 times
Share this document with a friend
Description:
Newer targets for diabetes
20
Metabolic disorder characterized by hyperglycemia, glycosuria, ketonemia and negative nitrogen balance Responsible for morbidity, not only in the developed countries but is gradually reaching epidemic proportions in the developing countries too With the increased prevalence of obesity in the general population, especially in young adults, the prevalence of diabetes is also on the rise, hence diabetes has been redefined as ‘diabesity’ or ‘obesity dependent diabetes mellitus As per International Diabetes Federation [IDF] Diabetes Atlas, 285 million people worldwide now suffer from diabetes If the current rate of growth continues unchecked number is expected to exceed 435 million in 2030 DIABETES MELLITUS 1
Transcript
Page 1: Newer Antidiabetic Agents.pptx

1

Metabolic disorder characterized by hyperglycemia, glycosuria, ketonemia and negative nitrogen balance

Responsible for morbidity, not only in the developed countries but is gradually reaching epidemic proportions in the developing countries too

With the increased prevalence of obesity in the general population, especially in young adults, the prevalence of diabetes is also on the rise, hence diabetes has been redefined as ‘diabesity’ or ‘obesity dependent diabetes mellitus

As per International Diabetes Federation [IDF] Diabetes Atlas, 285 million people worldwide now suffer from diabetes

If the current rate of growth continues unchecked number is expected to exceed 435 million in 2030

DIABETES MELLITUS

Page 2: Newer Antidiabetic Agents.pptx

2

Number of Cases with diabetes (20-79 years)

S. No. Country/Territory 2010(Millions)

2030(Millions)

1 India 50.8 87

2 China 43.2 62.6

3 USA 26.8 36.0

4 Russian Federation 9.6 10.3

5 Brazil 7.6 12.7

6 Germany 7.5 -

7 Pakistan 7.1 13.8

8 Japan 7.1 -

9 Indonesia 7.0 12.0

10 Mexico 6.8 11.9

Page 3: Newer Antidiabetic Agents.pptx

3

Universal symbol for diabetes

BLUE CIRCLE

“World Diabetes day was introduced in 1991 and is celebrated every year on November 14”. The day was

chosen to honor Frederick Banting (November 14, which is also his birthday), who along with Charles Best, first

conceived the idea that led to the discovery of insulin in 1921.

Page 4: Newer Antidiabetic Agents.pptx

4

TYPE 1 DIABETES MELLITUS (T1DM)

TYPE 2 DIABETES MELLITUS (T2DM)

GESTATIONAL DIABETES MELLITUS

Diabetes Mellitus

DELL
Page 5: Newer Antidiabetic Agents.pptx

5

TYPE 1 DIABETES MELLITUS (T1DM)

T1DM which was previously encompassed by the terms

insulin-dependent diabetes, type 1 diabetes, or juvenile-

onset diabetes

Accounts for only 5–10% of the cases

Cellular-mediated autoimmune destruction of the β-

cells of the pancreas

Page 6: Newer Antidiabetic Agents.pptx

6

TYPE 2 DIABETES MELLITUS (T2DM)

T2DM previously referred to as non–insulin dependent

diabetes, type 2 diabetes, or adult-onset diabetes

Accounts for approximately 90–95% of diabetes cases

The risk of developing T2DM increases with age,

obesity, and lack of physical activity

Page 7: Newer Antidiabetic Agents.pptx

7

GESTATIONAL DIABETES

Page 8: Newer Antidiabetic Agents.pptx

8

Complications of Diabetes Mellitus

Diabetes

Mellitus

Retinopathy

(26%)

Nephropathy

(5%)

Cardiovascular

Disorders

(17%)

Neuropathy

(28%)

Peripheral

Vascular Disorders

(6%)

Cerebrovascular

Disorders

(1%)

Page 9: Newer Antidiabetic Agents.pptx

9

Page 10: Newer Antidiabetic Agents.pptx

10

Page 11: Newer Antidiabetic Agents.pptx

11

Page 12: Newer Antidiabetic Agents.pptx

12

NORMAL GLUCOSE UPTAKE

Page 13: Newer Antidiabetic Agents.pptx

13

T1DM

Page 14: Newer Antidiabetic Agents.pptx

14

T2DM

Page 15: Newer Antidiabetic Agents.pptx

15

Type-2 Diabetes Mellitus

Page 16: Newer Antidiabetic Agents.pptx

16

DIAGNOSIS OF DIABETES MELLITUS

Fasting plasma glucose test (FPG;>126 mg/dl)

Oral glucose tolerance test (OGTT; >200 mg/dl 2 hr after

glucose challenge) glycation of hemoglobin A (HbA1c levels).8

HbA1c has been considered as the gold standard for glycemic

control monitoring.

In general, every percentage point drop in HbA1c reduces

the risk of microvascular complications by 40%. Other tests that are relevant for tracking disease progression

include fasting insulin to glucose ratios (insulin sensitivity) and lipid levels

Page 17: Newer Antidiabetic Agents.pptx

17

Current drug therapies used for the management of T2DM

Class of drug Drugs Role

Sulfonylureas

1st generation

2nd generation

3rd generation

Acetohexamide, Chlorpropamide,

Tolbutamide, TolazamideInsulin secretagogues

Glibenclamide, Glyburide,

Glipizide Insulin secretagogues

Glimepiride Insulin secretagogues

Meglitinides(Glinides)

Repaglinide, Nateglinide Insulin secretagogues

Biguanides Metformin, PhenforminInsulin sensitizers

Thiazolidinediones(PPAR γ agonists; Glitazones)

Rosiglitazone, Pioglitazone,Insulin sensitizers

Gliptins(DPP-1V inhibitors)

Sitagliptin, Saxagliptin Insulin secretagogues

Page 18: Newer Antidiabetic Agents.pptx

18

New Targets For The Management of T2DM

Target Role

Glycogen Synthase Kinase-3 (GSK-3) Inhibitors Activation of glycogen synthase

PPAR α/γ dual agonist Insulin sensitizers

Na+ glucose co-transporter (SGLT) inhibitors Inhibits renal glucose reabsorption from urine

HGO Inhibitors Insulin sensitizers & decrease insulin resistance

β3- Adrenoreceptor Agonist Decreases food consumption

Retinoid X receptor Controls lipid and carbohydrate metabolism

Protein Tyrosine Phosphatase 1B (PTP 1B) inhibitors

Prevents dephosphorylation of activated insulin receptor

Page 19: Newer Antidiabetic Agents.pptx

19

Algorithm for the treatment of diabetes

Page 20: Newer Antidiabetic Agents.pptx

THANKS

20


Recommended